A research programme by the Access to Medicine Foundation
The foundation

Access to Medicine Foundation

The Foundation stimulates and guides pharmaceutical companies to do more to improve access to medicine. It is an independent non-profit organisation.
Our programmes

Access to Medicine Index

Ranks 20 of the world’s largest pharmaceutical companies based on their efforts to address access to medicine, including in strategy, governance, R&D and pricing. By publicly recognising the best performers, the Index spurs companies to compete to be the best.

Antimicrobial Resistance Benchmark

Tracks what the 30 most active companies in antimicrobial R&D and manufacturing are doing to bring antimicrobial resistance under control. By assessing the level of action, it provides a reality check on progress against AMR.

Access to Vaccines Index

Reports what vaccine companies are doing to ensure all children can be immunised wherever they live. By uncovering what is working and where, this Index helps ensure vaccine markets also reach the poorest and most remote communities.
Type search term(s) and press enter
Often searched for
Index Ranking Vacancies 10-year analysis R&D pipelines AMR antibiotics Investors

In the media

Read how the global media covers how pharmaceutical companies respond to market trends and global health issues using the Foundation's research, and translates the complexity of access to medicine for the public.

All Access to Medicine Foundation Access to Medicine Index Antimicrobial Resistance Benchmark Access to Vaccines Index

13 May 2020

Investors are changing their view of pharma during the COVID-19 epidemic

In this article for Nikkei, Yoshinaru Sakabe delves into the reasons why the COVID-19 epidemic is spurring investors to look increasingly closely at h...

05 Mar 2020

Inside the race to find a coronavirus vaccine

Writing for Devex, Jenny Lei Ravelo looks at how the global health community is trying to fast-track the development of a vaccine against the&nbs...

27 Feb 2020

Access to Medicine: Mission Possible

Writing for the European Medical Group's GOLD magazine, Kristie Tuner looks at some of the challenges in improving access to medicine in developing co...

30 Aug 2019

Vaccine alliance in USD 7.4bn funding push

Gavi the Vaccine Alliance is seeking the funds to cover more vaccines, including plans to stockpile the forthcoming Ebola vaccine. Inga Vesp...

27 Aug 2019

Japan’s GHIT ramps up fight against neglected tropical diseases

Writing for the Financial Times Health Report, Andrew Jack explores the recent activity of Japan's Global Health Innovative Technology Fund (GHIT...

05 Aug 2019

How voluntary licensing agreements are transforming HIV care

Rebecca Root writes for Devex about the impact of voluntary licensing for the HIV medicine dolutegravir (DTG) in low-income countries. 

24 Jun 2019

Drug Companies Are Focusing on the Poor After Decades of Ignoring Them

Writing in The New York Times, Donald G. McNeil Jr. charts the progress made by pharmaceutical companies on access to medicine since the HIV/AIDS cris...

20 May 2019

Industry steps up interest in developing world, fueling doubling of R&D pipeline

The Foundation's 10-year analysis on the pharmaceutical industry and global health is covered by Nick Paul Taylor in this piece for FierceBiotech. Nic...

16 May 2019

Pharma industry improves access to medicines in developing world

Writing for the Financial Times, Clive Cookson covers the Foundation’s latest research report — the first 10-year analysis on how the pharmaceut...

16 May 2019

Pharma is making progress addressing global health, but it’s still a mixed bag

Ed Silverman of STAT news reports on the Foundation's first 10-year progress report on how pharmaceutical companies are responding to calls to improve...

01 Apr 2019

Access to medicines - business as usual?

The Lancet highlights key findings from the 2018 Access to Medicine Index, for example, that while all 20 pharmaceutical companies assessed...

18 Mar 2019

Pharma's Damaged Reputation

Meagan Parrish writes for Pharma Manufacturing, exploring pharma’s current reputation among the general public. Highlighting some of the recent critic...

06 Feb 2019

Insights and expectations on Japanese investors and pharmaceutical companies

Bowen Gu, Investor Engagement Manager at the Access to Medicine Foundation talks to Etsuya Hirose, Nakatsuka Kazunori and Ayaka Hirai in this QUICK ES...

20 Nov 2018

Cancer Breakthroughs Are Set to Elude World's Poor, Study Says

Writing for Bloomberg, Naomi Kresge covers the results of the latest Access to Medicine Index: "Giant drugmakers pouring resources into new...

20 Nov 2018

Big pharma failing to develop urgent drugs for poorest countries

Julia Kollewe of the Guardian covers the latest Access to Medicine Index: "most firms focus on infectious diseases such as HIV/Aids, malaria and tuber...

20 Nov 2018

Who are the best — and worst — among the major pharmas at developing drugs for the poor?

John Carroll of Endpoints News reports on the results of the 2018 Access to Medicine Index, highlighting the leaders in the Index, and noting those co...

Got a question?

Learn more

View our detailed overview of each company’s performance in the Index, including breakdowns of their product portfolios and R&D pipelines.

Back to top |